文献速递淋巴瘤造血干细胞移植与细胞治疗

CAR-T细胞治疗使复发原发性中枢神经系统淋巴瘤获得高比例长期缓解:LOC网络真实世界结果

CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real-life results of the LOC network.
PubMed 文献 · Am J Hematol · 2024-04-08

该回顾性研究从LOC网络数据库选取27例三线及以上接受白细胞分离的复发原发性中枢神经系统淋巴瘤(PCNSL)患者,其中25例接受CAR-T细胞(tisa-cel 16例、axi-cel 9例),并与247例对照比较。CAR-T组最佳完全缓解率64%,中位总生存21.2个月,疗效显著优于对照组,但细胞因子释放综合征和神经毒性发生率高。

要点

  • 25例接受CAR-T细胞治疗,最佳完全缓解率为64%。
  • 中位总生存21.2个月,1年无进展生存率43%后达平台期。
  • 23例发生细胞因子释放综合征,17/25例(68%)发生神经毒性,其中5例≥3级。

核心结论

  • CAR-T细胞在复发PCNSL中有效,长期缓解率高且耐受性总体可控。

研究设计与样本

  • 回顾性研究,从LOC网络数据库选取三线及以上接受白细胞分离的PCNSL患者,并以至少三线且不适合ASCT的PCNSL患者为对照。
  • CAR-T组27例接受白细胞分离(中位年龄68岁,中位既往三线治疗,其中14/27例曾接受ASCT),25例接受CAR-T细胞(tisa-cel 16例、axi-cel 9例),治疗时间为2020年至2023年。
  • 对照组247例。

主要发现

  • CAR-T细胞输注后最佳缓解为完全缓解16例(64%)。
  • 自白细胞分离起1年无进展生存率为43%,此后达平台期;输注时处于完全或部分缓解的患者1年无复发生存率为79%。
  • 中位总生存为21.2个月。
  • 23例发生细胞因子释放综合征,17/25例(68%)发生神经毒性(5例≥3级)。
  • 疗效终点CAR-T组显著优于对照组(N=247):中位无进展生存3个月,中位总生存4.7个月,p<0.001。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The prognosis of relapsed primary central nervous system lymphoma (PCNSL) remains dismal. CAR T-cells are a major contributor to systemic lymphomas, but their use in PCNSL is limited. From the LOC network database, we retrospectively selected PCNSL who had leukapheresis for CAR-T cells from the third line of treatment, and, as controls, PCNSL treated with any treatment, at least in the third line and considered not eligible for ASCT. Twenty-seven patients (median age: 68, median of three previous lines, including ASCT in 14/27) had leukapheresis, of whom 25 received CAR T-cells (tisa-cel: N = 16, axi-cel: N = 9) between 2020 and 2023. All but one received a bridging therapy. The median follow-up after leukapheresis was 20.8 months. The best response after CAR-T cells was complete response in 16 patients (64%). One-year progression-free survival from leukapheresis was 43% with a plateau afterward. One-year relapse-free survival was 79% for patients in complete or partial response at CAR T-cell infusion. The median overall survival was 21.2 months. Twenty-three patients experienced a cytokine release syndrome and 17/25 patients (68%) a neurotoxicity (five grade ≥3). The efficacy endpoints were significantly better in the CAR T-cell group than in the control group (N = 247) (median PFS: 3 months; median OS: 4.7 months; p < 0.001). This series represents the largest cohort of PCNSL treated with CAR T-cells reported worldwide. CAR T-cells are effective in relapsed PCNSL, with a high rate of long-term remission and a reassuring tolerance profile. The results seem clearly superior to those usually observed in this setting.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Choquet S, Soussain C, Azar N, et al. CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real-life results of the LOC network. Am J Hematol. 2024. PMID: 38586986. doi:10.1002/ajh.27316

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。